CR20220491A - Compuestos antivirales y métodos para la administración de los mismos - Google Patents

Compuestos antivirales y métodos para la administración de los mismos

Info

Publication number
CR20220491A
CR20220491A CR20220491A CR20220491A CR20220491A CR 20220491 A CR20220491 A CR 20220491A CR 20220491 A CR20220491 A CR 20220491A CR 20220491 A CR20220491 A CR 20220491A CR 20220491 A CR20220491 A CR 20220491A
Authority
CR
Costa Rica
Prior art keywords
administration
methods
covid
antiviral
antiviral compounds
Prior art date
Application number
CR20220491A
Other languages
English (en)
Inventor
John M H Gregg
Original Assignee
John M H Gregg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John M H Gregg filed Critical John M H Gregg
Publication of CR20220491A publication Critical patent/CR20220491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se relaciona con el uso de medicamentos antivirales con diferentes mecanismos de acción para tratar o prevenir infecciones virales como la COVID-19 (también conocida como SARS-CoV-2) y reducir las complicaciones médicas relacionadas con la enfermedad viral de la COVID-19. La presente invención también se refiere a composiciones y combinaciones de nuevos fármacos antivirales formados a partir de fármacos existentes con actividad antiviral, y la administración de estos compuestos usados en estas diversas combinaciones nuevas, que se incorporan en sistemas de administración pulmonar y oral
CR20220491A 2020-03-23 2021-03-23 Compuestos antivirales y métodos para la administración de los mismos CR20220491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062993121P 2020-03-23 2020-03-23
PCT/US2021/070300 WO2021195661A1 (en) 2020-03-23 2021-03-23 Anti-viral compounds and methods for administration thereof

Publications (1)

Publication Number Publication Date
CR20220491A true CR20220491A (es) 2022-12-12

Family

ID=77890599

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220491A CR20220491A (es) 2020-03-23 2021-03-23 Compuestos antivirales y métodos para la administración de los mismos

Country Status (20)

Country Link
US (2) US20230263778A1 (es)
EP (2) EP4110330A4 (es)
JP (2) JP2023519158A (es)
KR (2) KR20220158242A (es)
CN (2) CN120754260A (es)
AU (2) AU2021244718A1 (es)
BR (1) BR112022018236A2 (es)
CA (2) CA3170367A1 (es)
CL (1) CL2022002481A1 (es)
CO (1) CO2022014073A2 (es)
CR (1) CR20220491A (es)
DO (1) DOP2022000185A (es)
EC (1) ECSP22076862A (es)
GE (1) GEP20267884B (es)
IL (2) IL296152A (es)
MX (2) MX2022011370A (es)
PE (1) PE20221868A1 (es)
PH (1) PH12022552324A1 (es)
WO (1) WO2021195661A1 (es)
ZA (1) ZA202211060B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
CN118994170A (zh) 2020-03-12 2024-11-22 吉利德科学公司 制备1'-氰基核苷的方法
JP2023519158A (ja) * 2020-03-23 2023-05-10 グレッグ、ジョン、エムエイチ 抗ウィルス化合物
EP4132651B1 (en) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
CA3187821A1 (en) 2020-06-24 2021-12-30 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
WO2022047065A2 (en) 2020-08-27 2022-03-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
WO2023075714A1 (en) * 2021-10-25 2023-05-04 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder compositions comprising anti-viral agents
IT202100029909A1 (it) * 2021-11-26 2023-05-26 Craniomed Group S R L Combinazione di uno o più antibiotici della classe delle ansamicine con uno o più altri antibiotici per la prevenzione e il trattamento di infezioni causate da coronavirus, delle relative malattie e degli effetti clinici indotti dalle tossine prodotte a seguito dell’infezione da coronavirus.
TW202525810A (zh) 2022-03-02 2025-07-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
CN114568490B (zh) * 2022-04-01 2023-12-19 眉山职业技术学院(眉山技师学院) 雷帕霉素在抑制柑橘青霉菌生长中的应用
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2024249440A1 (en) * 2023-05-30 2024-12-05 Corcept Therapeutics Incorporated Pyrylium method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
CN120983460A (zh) * 2025-09-25 2025-11-21 中国农业科学院饲料研究所 泰乐菌素衍生物在制备抗痘病毒科病毒药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010043004A (ko) * 1998-04-30 2001-05-25 개리 이. 프라이드만 피코르나 바이러스 억제 화합물, 그의 제조 방법 및 용도
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US20050164994A1 (en) * 2001-12-10 2005-07-28 Control Deliver Systems, Inc. Treatment of genitourinary tract disorders
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
WO2005113580A1 (en) * 2004-05-21 2005-12-01 Pfizer Inc. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
CN101039701A (zh) * 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
JP2008535928A (ja) * 2005-04-12 2008-09-04 シヴィダ・インコーポレイテッド ＨＭＧＣｏＡ還元酵素インヒビターの組合せ及びその使用
WO2007016306A2 (en) * 2005-08-01 2007-02-08 Psivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
WO2008094507A2 (en) * 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Novel fusion compounds
US20170044096A1 (en) * 2013-03-15 2017-02-16 Rutgers, The State University Of New Jersey Augmenting Moieties for Anti-Inflammatory Compounds
WO2012138911A2 (en) * 2011-04-05 2012-10-11 The Administrators Of The Tulane Educational Fund Conjugates of anti-hiv drugs and somatostatin analogs
WO2015051268A2 (en) * 2013-10-04 2015-04-09 The Johns Hopkins University Hiv protease inhibitors against picornavirus infection
HRP20220355T1 (hr) * 2015-09-16 2022-05-13 Gilead Sciences, Inc. Postupci za liječenje infekcija coronaviridae
WO2020081874A1 (en) * 2018-10-18 2020-04-23 Respira Technologies, Inc. Electronic device for producing an aerosol for inhalation by a person
EP4114384A1 (en) * 2020-03-06 2023-01-11 Pfizer Inc. Methods of inhibiting sars-cov-2 replication and treating coronavirus disease 2019
CN115315252A (zh) * 2020-03-22 2022-11-08 盈擘医药股份有限公司 用于预防或暴露后治疗感染或呼吸疾病的抗病毒组合物
JP2023519158A (ja) * 2020-03-23 2023-05-10 グレッグ、ジョン、エムエイチ 抗ウィルス化合物
CN111450088B (zh) * 2020-04-30 2021-08-03 上海爱启医药技术有限公司 二杨梅素基二硒醚的药物应用

Also Published As

Publication number Publication date
IL296152A (en) 2022-11-01
KR20250126146A (ko) 2025-08-22
PE20221868A1 (es) 2022-12-02
ECSP22076862A (es) 2022-11-30
CL2022002481A1 (es) 2023-02-10
JP2023519158A (ja) 2023-05-10
EP4628100A3 (en) 2025-12-17
EP4110330A1 (en) 2023-01-04
GEP20267884B (en) 2026-04-27
JP2025166040A (ja) 2025-11-05
ZA202211060B (en) 2023-12-20
EP4110330A4 (en) 2024-04-03
CA3170367A1 (en) 2021-09-30
CO2022014073A2 (es) 2022-10-31
US20230201167A1 (en) 2023-06-29
US20230263778A1 (en) 2023-08-24
MX2022011370A (es) 2022-10-07
PH12022552324A1 (en) 2023-12-04
CA3280568A1 (en) 2025-10-28
DOP2022000185A (es) 2023-01-31
AU2021244718A1 (en) 2022-11-03
US12285413B2 (en) 2025-04-29
AU2025217394A1 (en) 2025-09-04
EP4628100A2 (en) 2025-10-08
MX2025008873A (es) 2025-09-02
KR20220158242A (ko) 2022-11-30
WO2021195661A1 (en) 2021-09-30
CN115697328A (zh) 2023-02-03
IL323820A (en) 2025-12-01
BR112022018236A2 (pt) 2022-10-25
CN120754260A (zh) 2025-10-10

Similar Documents

Publication Publication Date Title
ECSP22076862A (es) Compuestos antivirales y métodos para la administración de los mismos
GEAP202316298A (en) Highly active compounds against covid-19
ECSP21051833A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
ECSP23030959A (es) Compuestos y su uso en el tratamiento del cáncer
CO2022011728A2 (es) Composiciones y usos de glp-1
PH12022553530A1 (en) 1'-cyano nucleoside analogs and uses thereof
BR112022004424A2 (pt) Pró-fármacos antivirais e formulações dos mesmos
UY37168A (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
CL2004000590A1 (es) Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v
MX2020008017A (es) Formulaciones de vidrio y usos de las mismas.
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
MX2021004566A (es) Compuestos terapeuticos.
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
CO2019010029A2 (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer
AR114082A1 (es) INHIBIDORES DE LA PI4KIIIb
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
BR112023019795A2 (pt) Composições nasais compreendendo alcaftadina
AR111464A1 (es) Terapia combinada para el tratamiento de infecciones virales
BR112023026356A2 (pt) Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c
MX2022010938A (es) Compuestos de yodo para el tratamiento de patogenos respiratorios.
SV2006002192A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa ie
CL2025002072A1 (es) Inhibidores de prmt5–mta.